Related Experiment Video

Updated: Jun 28, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

New drugs for the treatment of lymphoma

Luca Paoluzzi1, Yukiko Kitagawa, Matko Kalac

  • 1Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St. Nicholas Avenue, Room 216, New York, NY 10032, USA.

Hematology/Oncology Clinics of North America
|October 29, 2008
PubMed

Insights

Innovative drugs targeting specific genetic lesions in blood cancers like chronic myelogenous leukemia (CML) are revolutionizing treatment. This shift allows for targeted therapies in lymphomas and other hematologic malignancies.

Area of Science:

  • Hematologic oncology
  • Pharmacology
  • Molecular biology

Background:

  • Historically, solid tumors dominated drug development for hematologic malignancies.
  • The success of imatinib in chronic myelogenous leukemia (CML) marked a paradigm shift.
  • New targeted therapies are now emerging for blood cancers.

Purpose of the Study:

  • To highlight innovative drug development in lymphoma.
  • To emphasize the biologic basis of novel therapeutic approaches.
  • To link fundamental biology to biochemical pharmacology.

Main Methods:

  • Review of recent advancements in lymphoma drug development.
  • Focus on novel molecular targets.
  • Integration of biologic rationale with pharmacological strategies.

Main Results:

  • Identification of key targets such as Syk, Bcl-2, CD-40, and the PI3K/AKT/mTOR pathway.
  • Demonstration of targeted therapies' efficacy in hematologic malignancies.
  • Shift towards precision medicine in blood cancer treatment.

Conclusions:

  • Targeted therapies based on specific molecular lesions are transforming lymphoma treatment.
  • Understanding the biologic underpinnings is crucial for developing effective drugs.
  • The future of hematologic oncology lies in precision medicine and novel drug targets.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...